What is Aclaris Therapeutics Inc's earnings per share (EPS)?

Aclaris Therapeutics Inc (ACRS) reported diluted earnings per share of $-0.53 for fiscal year 2025. This represents a 69.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aclaris Therapeutics Inc Financials

ACRS

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Aclaris Therapeutics Inc (ACRS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ACRS FY2025 2026-05-07

The business remains a cash-consuming R&D platform, with minimal capital spending and only a small commercial revenue base.

FY2025’s narrower accounting loss of $64.9M looked better than FY2024’s $132.1M. But revenue fell to $7.8M and operating cash burn reached -$47.1M, so the better loss figure appears to reflect expense mix more than stronger sales productivity or cleaner profit-to-cash conversion.

With R&D spending at $52.6M against just $7.8M of revenue, the company is still funding science rather than monetizing it at scale. Free cash flow of -$47.2M almost matched operating cash flow of -$47.1M, showing the cash drain comes from ongoing operations, not heavy physical reinvestment.

The balance sheet still provides near-term liquidity: equity exceeds liabilities and the current ratio remains 3.4x, which is very different from a debt-driven structure. But cash of $20.0M is well below the latest operating cash burn of -$47.1M, so sustaining the current research pace depends on assets beyond cash or fresh financing.

Financial Health Signals

Financial Health Score 44/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Aclaris Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-1.12

Aclaris Therapeutics Inc scores -1.12, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($797.5M) relative to total liabilities ($57.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

Aclaris Therapeutics Inc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.73x

For every $1 of reported earnings, Aclaris Therapeutics Inc generates $0.73 in operating cash flow (-$47.1M OCF vs -$64.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$7.8M

YoY-58.2%

5Y CAGR+3.8%

Aclaris Therapeutics Inc generated $7.8M in revenue in fiscal year 2025. This represents a decrease of 58.2% from the prior year.

EBITDA

-$75.9M

YoY+46.2%

Aclaris Therapeutics Inc's EBITDA was -$75.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 46.2% from the prior year.

Net Income

-$64.9M

YoY+50.8%

Aclaris Therapeutics Inc reported -$64.9M in net income in fiscal year 2025. This represents an increase of 50.8% from the prior year.

EPS (Diluted)

$-0.53

YoY+69.0%

Aclaris Therapeutics Inc earned $-0.53 per diluted share (EPS) in fiscal year 2025. This represents an increase of 69.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$47.2M

YoY-133.8%

Aclaris Therapeutics Inc generated -$47.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 133.8% from the prior year.

Cash & Debt

$20.0M

YoY-18.8%

5Y CAGR-2.0%

10Y CAGR+7.3%

Aclaris Therapeutics Inc held $20.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

121M

YoY+11.7%

5Y CAGR+18.4%

10Y CAGR+19.6%

Aclaris Therapeutics Inc had 121M shares outstanding in fiscal year 2025. This represents an increase of 11.7% from the prior year.

Margins & Returns

Gross Margin

73.3%

YoY-11.8pp

5Y CAGR+52.5pp

Aclaris Therapeutics Inc's gross margin was 73.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 11.8 percentage points from the prior year.

Operating Margin

-975.9%

YoY-217.7pp

5Y CAGR-190.5pp

Aclaris Therapeutics Inc's operating margin was -975.9% in fiscal year 2025, reflecting core business profitability. This is down 217.7 percentage points from the prior year.

Net Margin

-829.6%

YoY-124.1pp

5Y CAGR-42.5pp

Aclaris Therapeutics Inc's net profit margin was -829.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 124.1 percentage points from the prior year.

Return on Equity

-63.0%

YoY+21.9pp

5Y CAGR+72.5pp

10Y CAGR-40.8pp

Aclaris Therapeutics Inc's ROE was -63.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 21.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$52.6M

YoY+56.7%

5Y CAGR+12.4%

10Y CAGR+13.1%

Aclaris Therapeutics Inc invested $52.6M in research and development in fiscal year 2025. This represents an increase of 56.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$111K

YoY-8.3%

5Y CAGR-24.5%

10Y CAGR-14.1%

Aclaris Therapeutics Inc invested $111K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 8.3% from the prior year.

ACRS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$7.8M-58.2%	$18.7M-40.1%	$31.2M+5.0%	$29.8M+340.1%	$6.8M+4.3%	$6.5M
Cost of Revenue	$2.1M-25.1%	$2.8M-18.4%	$3.4M-14.9%	$4.0M-14.6%	$4.7M-8.2%	$5.1M
Gross Profit	$5.7M-64.0%	$15.9M-42.8%	$27.8M+8.2%	$25.7M+1156.3%	$2.0M+51.8%	$1.3M
R&D Expenses	$52.6M+56.7%	$33.6M-65.9%	$98.4M+26.4%	$77.8M+77.6%	$43.8M+49.3%	$29.3M
SG&A Expenses	$22.0M-1.0%	$22.2M-31.5%	$32.4M+29.0%	$25.1M+6.4%	$23.6M+15.0%	$20.5M
Operating Income	-$76.4M+46.2%	-$141.9M-45.8%	-$97.4M-8.4%	-$89.9M-0.1%	-$89.7M-76.2%	-$50.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	-$367K	N/A	N/A	-$182K
Net Income	-$64.9M+50.8%	-$132.1M-49.3%	-$88.5M-1.8%	-$86.9M+4.4%	-$90.9M-78.1%	-$51.0M
EPS (Diluted)	$-0.53+69.0%	$-1.71-34.6%	$-1.27+4.5%	$-1.33+16.9%	$-1.60-33.3%	$-1.20

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$2.0M+54.1%	$1.3M-60.7%	$3.3M+85.6%	$1.8M+22.1%	$1.5M-84.2%	$9.2M+111.9%	$4.3M+57.1%	$2.8M
Cost of Revenue	$395K-25.8%	$532K-1.1%	$538K+4.5%	$515K+1.8%	$506K-28.2%	$705K+7.8%	$654K+4.8%	$624K
Gross Profit	$1.6M+109.8%	$763K-72.4%	$2.8M+118.8%	$1.3M+33.0%	$949K-88.8%	$8.5M+130.4%	$3.7M+72.4%	$2.1M
R&D Expenses	$15.7M-5.6%	$16.6M+27.3%	$13.0M+13.8%	$11.4M-1.2%	$11.6M+28.3%	$9.0M+51.5%	$6.0M-32.0%	$8.8M
SG&A Expenses	$6.7M+20.9%	$5.6M+14.5%	$4.9M-9.6%	$5.4M-12.3%	$6.1M+23.9%	$5.0M-12.4%	$5.7M+19.0%	$4.8M
Operating Income	-$22.2M+2.4%	-$22.7M-32.6%	-$17.1M+6.8%	-$18.4M-1.8%	-$18.1M+81.9%	-$99.7M-851.9%	-$10.5M+18.5%	-$12.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$19.8M-0.1%	-$19.8M-35.5%	-$14.6M+5.3%	-$15.4M-2.3%	-$15.1M+84.4%	-$96.6M-1172.8%	-$7.6M+30.9%	-$11.0M
EPS (Diluted)	$-0.15	N/A	$-0.12+7.7%	$-0.13-8.3%	$-0.12	N/A	$-0.11+26.7%	$-0.15

ACRS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$160.5M-27.2%	$220.3M+11.6%	$197.4M-22.5%	$254.6M+1.3%	$251.2M+254.9%	$70.8M
Current Assets	$96.3M-23.5%	$126.0M-2.3%	$128.9M-44.4%	$231.6M+12.9%	$205.0M+256.6%	$57.5M
Cash & Equivalents	$20.0M-18.8%	$24.6M-38.4%	$39.9M-11.9%	$45.3M+65.6%	$27.3M+24.0%	$22.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$318K+6.7%	$298K-38.4%	$484K-22.3%	$623K-19.3%	$772K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$57.4M-11.4%	$64.8M+61.0%	$40.2M-29.4%	$57.0M+5.8%	$53.9M+62.6%	$33.1M
Current Liabilities	$28.6M-9.3%	$31.6M+2.1%	$31.0M+41.1%	$21.9M-4.3%	$22.9M+54.2%	$14.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$10.7M
Total Equity	$103.1M-33.7%	$155.6M-1.0%	$157.2M-20.5%	$197.6M+0.1%	$197.3M+424.1%	$37.6M
Retained Earnings	-$967.8M-7.2%	-$902.9M-17.1%	-$770.8M-13.0%	-$682.3M-14.6%	-$595.4M-18.0%	-$504.5M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$198.7M+23.8%	$160.5M-8.6%	$175.5M-7.2%	$189.1M-4.5%	$198.1M-10.1%	$220.3M+20.8%	$182.4M+13.2%	$161.1M
Current Assets	$110.2M+14.4%	$96.3M-4.3%	$100.6M-3.5%	$104.2M-4.2%	$108.8M-13.6%	$126.0M-4.8%	$132.3M+12.5%	$117.6M
Cash & Equivalents	$28.7M+43.6%	$20.0M-21.0%	$25.3M-0.6%	$25.4M-16.3%	$30.4M+23.6%	$24.6M-48.4%	$47.7M+108.7%	$22.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$194K-22.4%	$250K-21.4%	$318K-7.3%	$343K+5.5%	$325K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$55.1M-4.0%	$57.4M+3.5%	$55.4M-3.4%	$57.4M+6.3%	$54.0M-16.6%	$64.8M+24.0%	$52.2M+91.7%	$27.2M
Current Liabilities	$27.4M-4.5%	$28.6M+11.8%	$25.6M-4.5%	$26.8M+24.8%	$21.5M-31.9%	$31.6M+67.9%	$18.8M+20.0%	$15.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$143.6M+39.4%	$103.1M-14.2%	$120.1M-8.8%	$131.7M-8.6%	$144.1M-7.4%	$155.6M+19.5%	$130.2M-2.7%	$133.8M
Retained Earnings	-$987.6M-2.0%	-$967.8M-2.1%	-$948.0M-1.6%	-$933.4M-1.7%	-$917.9M-1.7%	-$902.9M-12.0%	-$806.3M-0.9%	-$798.7M

ACRS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$47.1M-134.7%	-$20.1M+74.4%	-$78.3M-15.9%	-$67.6M-29.6%	-$52.1M-34.9%	-$38.6M
Capital Expenditures	$111K-8.3%	$121K-90.8%	$1.3M+116.4%	$605K+96.4%	$308K-32.0%	$453K
Free Cash Flow	-$47.2M-133.8%	-$20.2M+74.6%	-$79.6M-16.8%	-$68.2M-30.0%	-$52.4M-34.2%	-$39.1M
Investing Cash Flow	$48.4M+169.3%	-$69.8M-250.9%	$46.2M+266.0%	$12.6M+107.5%	-$167.6M-2724.6%	$6.4M
Financing Cash Flow	-$5.9M-107.9%	$74.5M+179.1%	$26.7M-63.3%	$72.9M-67.6%	$225.1M+1125.0%	$18.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$18.1M-38.2%	-$13.1M-20.1%	-$10.9M-9.4%	-$10.0M+23.5%	-$13.1M-46.1%	-$8.9M-140.6%	$22.0M+278.5%	-$12.3M
Capital Expenditures	$13K-45.8%	$24K+4.3%	$23K+9.5%	$21K-51.2%	$43K	$0	$0+100.0%	-$14K
Free Cash Flow	-$18.2M-38.1%	-$13.2M-20.1%	-$11.0M-9.4%	-$10.0M+23.6%	-$13.1M-46.6%	-$8.9M-140.6%	$22.0M+278.3%	-$12.3M
Investing Cash Flow	-$30.9M-398.3%	$10.4M-25.0%	$13.8M+174.0%	$5.0M-73.6%	$19.1M+121.5%	-$88.7M-3274.3%	$2.8M+514.7%	-$674K
Financing Cash Flow	$57.8M+2380.2%	-$2.5M+16.8%	-$3.0M-33722.2%	-$9K+96.7%	-$275K-100.4%	$74.6M+338900.0%	$22K+300.0%	-$11K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ACRS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	73.3%-11.8pp	85.1%-4.0pp	89.0%+2.6pp	86.5%+56.2pp	30.3%+9.5pp	20.8%
Operating Margin	-975.9%-217.7pp	-758.2%-446.6pp	-311.6%-9.5pp	-302.0%+1025.1pp	-1327.1%-541.6pp	-785.4%
Net Margin	-829.6%-124.1pp	-705.5%-422.3pp	-283.2%+9.0pp	-292.1%+1051.8pp	-1344.0%-556.9pp	-787.0%
Return on Equity	-63.0%+21.9pp	-84.9%-28.6pp	-56.3%-12.3pp	-44.0%+2.1pp	-46.0%+89.5pp	-135.5%
Return on Assets	-40.5%+19.5pp	-59.9%-15.1pp	-44.8%-10.7pp	-34.1%+2.0pp	-36.2%+35.9pp	-72.1%
Current Ratio	3.36-0.6	3.99-0.2	4.16-6.4	10.55+1.6	8.94+5.1	3.87
Debt-to-Equity	0.56+0.1	0.42+0.2	0.26-0.0	0.29+0.0	0.270.0	0.28
FCF Margin	-603.4%-495.5pp	-107.9%+147.0pp	-254.8%-25.7pp	-229.1%+546.5pp	-775.6%-172.7pp	-603.0%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	80.2%+21.3pp	58.9%-24.8pp	83.7%+12.7pp	71.0%+5.8pp	65.2%-27.1pp	92.3%+7.4pp	85.0%+7.5pp	77.4%
Operating Margin	-1111.8%+643.7pp	-1755.5%-1235.7pp	-519.8%+516.1pp	-1035.9%+207.0pp	-1242.9%-160.6pp	-1082.3%-841.3pp	-240.9%+223.8pp	-464.7%
Net Margin	-993.2%+535.4pp	-1528.6%-1085.6pp	-443.0%+425.3pp	-868.3%+168.5pp	-1036.8%+11.6pp	-1048.3%-873.8pp	-174.6%+222.6pp	-397.2%
Return on Equity	-13.8%+5.4pp	-19.2%-7.0pp	-12.2%-0.5pp	-11.7%-1.2pp	-10.5%+51.6pp	-62.1%-56.2pp	-5.8%+2.4pp	-8.2%
Return on Assets	-10.0%+2.4pp	-12.3%-4.0pp	-8.3%-0.2pp	-8.2%-0.5pp	-7.6%+36.2pp	-43.8%-39.7pp	-4.2%+2.7pp	-6.8%
Current Ratio	4.03+0.7	3.36-0.6	3.92+0.0	3.88-1.2	5.06+1.1	3.99-3.0	7.03-0.5	7.50
Debt-to-Equity	0.38-0.2	0.56+0.1	0.46+0.0	0.44+0.1	0.38-0.0	0.42+0.0	0.40+0.2	0.20
FCF Margin	-909.9%+105.9pp	-1015.8%-683.8pp	-332.1%+231.5pp	-563.5%+336.8pp	-900.3%-803.3pp	-97.0%-603.3pp	506.2%+952.2pp	-446.0%

Similar Companies

Tiziana Life Sciences Ltd Com TLSA

$160.3M

Innate Pharma Sa IPHA

$168.1M

Immutep IMMP

$62.0M

Proqr Therapeuti PRQR

$248.4M

Silence Therapeutics Plc SLN

$465.7M

Frequently Asked Questions

What is Aclaris Therapeutics Inc's annual revenue?

Aclaris Therapeutics Inc (ACRS) reported $7.8M in total revenue for fiscal year 2025. This represents a -58.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Aclaris Therapeutics Inc's revenue growing?

Aclaris Therapeutics Inc (ACRS) revenue declined by 58.2% year-over-year, from $18.7M to $7.8M in fiscal year 2025.

Is Aclaris Therapeutics Inc profitable?

No, Aclaris Therapeutics Inc (ACRS) reported a net income of -$64.9M in fiscal year 2025, with a net profit margin of -829.6%.

What is Aclaris Therapeutics Inc's EBITDA?

Aclaris Therapeutics Inc (ACRS) had EBITDA of -$75.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Aclaris Therapeutics Inc's gross margin?

Aclaris Therapeutics Inc (ACRS) had a gross margin of 73.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Aclaris Therapeutics Inc's operating margin?

Aclaris Therapeutics Inc (ACRS) had an operating margin of -975.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Aclaris Therapeutics Inc's net profit margin?

Aclaris Therapeutics Inc (ACRS) had a net profit margin of -829.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Aclaris Therapeutics Inc's return on equity (ROE)?

Aclaris Therapeutics Inc (ACRS) has a return on equity of -63.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Aclaris Therapeutics Inc's free cash flow?

Aclaris Therapeutics Inc (ACRS) generated -$47.2M in free cash flow during fiscal year 2025. This represents a -133.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Aclaris Therapeutics Inc's operating cash flow?

Aclaris Therapeutics Inc (ACRS) generated -$47.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Aclaris Therapeutics Inc's total assets?

Aclaris Therapeutics Inc (ACRS) had $160.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Aclaris Therapeutics Inc's capital expenditures?

Aclaris Therapeutics Inc (ACRS) invested $111K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Aclaris Therapeutics Inc spend on research and development?

Aclaris Therapeutics Inc (ACRS) invested $52.6M in research and development during fiscal year 2025.

How many shares does Aclaris Therapeutics Inc have outstanding?

Aclaris Therapeutics Inc (ACRS) had 121M shares outstanding as of fiscal year 2025.

What is Aclaris Therapeutics Inc's current ratio?

Aclaris Therapeutics Inc (ACRS) had a current ratio of 3.36 as of fiscal year 2025, which is generally considered healthy.

What is Aclaris Therapeutics Inc's debt-to-equity ratio?

Aclaris Therapeutics Inc (ACRS) had a debt-to-equity ratio of 0.56 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Aclaris Therapeutics Inc's return on assets (ROA)?

Aclaris Therapeutics Inc (ACRS) had a return on assets of -40.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Aclaris Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Aclaris Therapeutics Inc (ACRS) had $20.0M in cash against an annual operating cash burn of $47.1M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Aclaris Therapeutics Inc's Altman Z-Score?

Aclaris Therapeutics Inc (ACRS) has an Altman Z-Score of -1.12, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Aclaris Therapeutics Inc's Piotroski F-Score?

Aclaris Therapeutics Inc (ACRS) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Aclaris Therapeutics Inc's earnings high quality?

Aclaris Therapeutics Inc (ACRS) has an earnings quality ratio of 0.73x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Aclaris Therapeutics Inc?

Aclaris Therapeutics Inc (ACRS) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.